# ARS Pharmaceuticals, Inc.: financial statements, quarterly

SPRY · Nasdaq · CIK 1671858 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/spry.md) · [Financials](/companies/spry/financials.md) · [Filings](/companies/spry/filings.md) · [Insiders](/companies/spry/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/spry/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-125924.md) | [0.0 d](/filings/0000950170-25-042320.md) | [0.0](/filings/0000950170-25-070900.md) | [0.5](/filings/0000950170-25-107618.md) | [2.1](/filings/0001193125-25-273111.md) | [86.6 d](/filings/0001193125-26-097478.md) | [8.0](/filings/0001193125-26-225142.md) | [15.7](/filings/0001193125-26-349140.md) | [32.5](/filings/0001193125-25-273111.md) | [28.1 d](/filings/0001193125-26-097478.md) | [22.7](/filings/0001193125-26-225142.md) | [33.7](/filings/0001193125-26-349140.md) |
| Research and development | $m | [3.0](/filings/0000950170-24-125924.md) | [3.4 d](/filings/0000950170-25-042320.md) | [5.2](/filings/0000950170-25-070900.md) | [6.9](/filings/0000950170-25-107618.md) | [4.4](/filings/0001193125-25-273111.md) | [3.0 d](/filings/0001193125-26-097478.md) | [3.0](/filings/0001193125-26-225142.md) | [4.0](/filings/0001193125-26-349140.md) | [2.8](/filings/0001193125-25-273111.md) | [3.4 d](/filings/0001193125-26-097478.md) | [4.3](/filings/0001193125-26-225142.md) | [4.7](/filings/0001193125-26-349140.md) |
| Selling, general and administrative | $m | [15.0](/filings/0000950170-24-125924.md) | [6.8 d](/filings/0000950170-25-042320.md) | [8.0](/filings/0000950170-25-070900.md) | [8.9](/filings/0000950170-25-107618.md) | [19.3](/filings/0001193125-25-273111.md) | [35.5 d](/filings/0001193125-26-097478.md) | [41.1](/filings/0001193125-26-225142.md) | [54.3](/filings/0001193125-26-349140.md) | [74.8](/filings/0001193125-25-273111.md) | [60.0 d](/filings/0001193125-26-097478.md) | [72.2](/filings/0001193125-26-225142.md) | [77.6](/filings/0001193125-26-349140.md) |
| Operating income | $m | [(18.0)](/filings/0000950170-24-125924.md) | [(10.2) d](/filings/0000950170-25-042320.md) | [(13.2)](/filings/0000950170-25-070900.md) | [(15.3)](/filings/0000950170-25-107618.md) | [(21.7)](/filings/0001193125-25-273111.md) | [47.2 d](/filings/0001193125-26-097478.md) | [(37.2)](/filings/0001193125-26-225142.md) | [(47.6)](/filings/0001193125-26-349140.md) | [(53.2)](/filings/0001193125-25-273111.md) | [(41.5) d](/filings/0001193125-26-097478.md) | [(60.1)](/filings/0001193125-26-225142.md) | [(61.5)](/filings/0001193125-26-349140.md) |
| Net income | $m | [(14.9)](/filings/0000950170-24-125924.md) | [(7.2) d](/filings/0000950170-25-042320.md) | [(10.3)](/filings/0000950170-25-070900.md) | [(12.5)](/filings/0000950170-25-107618.md) | [(19.1)](/filings/0001193125-25-273111.md) | [49.9 d](/filings/0001193125-26-097478.md) | [(33.9)](/filings/0001193125-26-225142.md) | [(44.9)](/filings/0001193125-26-349140.md) | [(51.2)](/filings/0001193125-25-273111.md) | [(41.3) d](/filings/0001193125-26-097478.md) | [(60.6)](/filings/0001193125-26-225142.md) | [(62.3)](/filings/0001193125-26-349140.md) |
| Diluted EPS | $ per share | [(0.16)](/filings/0000950170-24-125924.md) | not reported | [(0.11)](/filings/0000950170-25-070900.md) | [(0.13)](/filings/0000950170-25-107618.md) | [(0.20)](/filings/0001193125-25-273111.md) | not reported | [(0.35)](/filings/0001193125-26-225142.md) | [(0.46)](/filings/0001193125-26-349140.md) | [(0.52)](/filings/0001193125-25-273111.md) | not reported | [(0.61)](/filings/0001193125-26-225142.md) | [(0.63)](/filings/0001193125-26-349140.md) |
| Basic EPS | $ per share | [(0.16)](/filings/0000950170-24-125924.md) | not reported | [(0.11)](/filings/0000950170-25-070900.md) | [(0.13)](/filings/0000950170-25-107618.md) | [(0.20)](/filings/0001193125-25-273111.md) | not reported | [(0.35)](/filings/0001193125-26-225142.md) | [(0.46)](/filings/0001193125-26-349140.md) | [(0.52)](/filings/0001193125-25-273111.md) | not reported | [(0.61)](/filings/0001193125-26-225142.md) | [(0.63)](/filings/0001193125-26-349140.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [60.5](/filings/0000950170-23-061996.md) | [71.0](/filings/0000950170-25-042320.md) | [56.0](/filings/0000950170-24-056967.md) | [36.6](/filings/0000950170-24-091776.md) | [39.7](/filings/0000950170-24-125924.md) | [50.8](/filings/0001193125-26-097478.md) | [39.9](/filings/0000950170-25-070900.md) | [51.5](/filings/0000950170-25-107618.md) | [59.6](/filings/0001193125-25-273111.md) | [41.3](/filings/0001193125-26-349140.md) | [24.3](/filings/0001193125-26-225142.md) | [8.2](/filings/0001193125-26-349140.md) |
| Current assets | $m | [244](/filings/0000950170-23-061996.md) | [232](/filings/0000950170-25-042320.md) | [226](/filings/0000950170-24-056967.md) | [221](/filings/0000950170-24-091776.md) | [209](/filings/0000950170-24-125924.md) | [334](/filings/0001193125-26-097478.md) | [304](/filings/0000950170-25-070900.md) | [281](/filings/0000950170-25-107618.md) | [339](/filings/0001193125-25-273111.md) | [285](/filings/0001193125-26-349140.md) | [245](/filings/0001193125-26-225142.md) | [212](/filings/0001193125-26-349140.md) |
| Total assets | $m | [249](/filings/0000950170-23-061996.md) | [233](/filings/0000950170-25-042320.md) | [228](/filings/0000950170-24-056967.md) | [222](/filings/0000950170-24-091776.md) | [218](/filings/0000950170-24-125924.md) | [351](/filings/0001193125-26-097478.md) | [327](/filings/0000950170-25-070900.md) | [313](/filings/0000950170-25-107618.md) | [373](/filings/0001193125-25-273111.md) | [328](/filings/0001193125-26-349140.md) | [288](/filings/0001193125-26-225142.md) | [249](/filings/0001193125-26-349140.md) |
| Current liabilities | $m | [11.2](/filings/0000950170-23-061996.md) | [2.4](/filings/0000950170-25-042320.md) | [3.7](/filings/0000950170-24-056967.md) | [6.7](/filings/0000950170-24-091776.md) | [16.6](/filings/0000950170-24-125924.md) | [23.4](/filings/0001193125-26-097478.md) | [27.6](/filings/0000950170-25-070900.md) | [45.6](/filings/0000950170-25-107618.md) | [50.9](/filings/0001193125-25-273111.md) | [39.1](/filings/0001193125-26-349140.md) | [49.6](/filings/0001193125-26-225142.md) | [60.9](/filings/0001193125-26-349140.md) |
| Total liabilities | $m | [11.3](/filings/0000950170-23-061996.md) | [2.4](/filings/0000950170-25-042320.md) | [3.7](/filings/0000950170-24-056967.md) | [6.7](/filings/0000950170-24-091776.md) | [16.6](/filings/0000950170-24-125924.md) | [94.4](/filings/0001193125-26-097478.md) | [98.3](/filings/0000950170-25-070900.md) | [121](/filings/0000950170-25-107618.md) | [225](/filings/0001193125-25-273111.md) | [213](/filings/0001193125-26-349140.md) | [226](/filings/0001193125-26-225142.md) | [237](/filings/0001193125-26-349140.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-097478.md) | not reported | not reported | [96.2](/filings/0001193125-25-273111.md) | [96.4](/filings/0001193125-26-349140.md) | [96.5](/filings/0001193125-26-225142.md) | [96.7](/filings/0001193125-26-349140.md) |
| Shareholders' equity | $m | [237](/filings/0000950170-24-125924.md) | [231](/filings/0001193125-26-097478.md) | [224](/filings/0001193125-25-273111.md) | [215](/filings/0001193125-25-273111.md) | [201](/filings/0001193125-25-273111.md) | [257](/filings/0001193125-26-349140.md) | [229](/filings/0001193125-26-349140.md) | [192](/filings/0001193125-26-349140.md) | [148](/filings/0001193125-25-273111.md) | [114](/filings/0001193125-26-349140.md) | [61.3](/filings/0001193125-26-349140.md) | [12.5](/filings/0001193125-26-349140.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(12.8) d](/filings/0000950170-24-125924.md) | [(17.4) d](/filings/0000950170-25-042320.md) | [(6.7)](/filings/0000950170-25-070900.md) | [(7.3) d](/filings/0000950170-25-107618.md) | [(14.5) d](/filings/0001193125-25-273111.md) | [42.0 d](/filings/0001193125-26-097478.md) | [(40.7)](/filings/0001193125-26-225142.md) | [(39.6) d](/filings/0001193125-26-349140.md) | [(47.0) d](/filings/0001193125-25-273111.md) | [(43.5) d](/filings/0001193125-26-097478.md) | [(44.9)](/filings/0001193125-26-225142.md) | [(60.9) d](/filings/0001193125-26-349140.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-125924.md) | [(0.1) d](/filings/0000950170-25-042320.md) | [0.1](/filings/0000950170-25-070900.md) | [0.0 d](/filings/0000950170-25-107618.md) | [0.1 d](/filings/0001193125-25-273111.md) | [0.3 d](/filings/0001193125-26-097478.md) | [0.1](/filings/0001193125-26-225142.md) | [0.1 d](/filings/0001193125-26-349140.md) | [0.2 d](/filings/0001193125-25-273111.md) | [0.0 d](/filings/0001193125-26-097478.md) | [0.0](/filings/0001193125-26-225142.md) | [0.0 d](/filings/0001193125-26-349140.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [30.8](/filings/0000950170-23-061996.md) | [94.2](/filings/0000950170-24-056967.md) | [94.9](/filings/0000950170-24-091776.md) | [95.6](/filings/0000950170-24-125924.md) | [96.5](/filings/0000950170-25-070900.md) | [96.8](/filings/0000950170-25-107618.md) | [97.0](/filings/0001193125-25-273111.md) | [98.1](/filings/0001193125-26-225142.md) | [98.4](/filings/0001193125-26-349140.md) | [98.8](/filings/0001193125-25-273111.md) | [99.3](/filings/0001193125-26-225142.md) | [99.3](/filings/0001193125-26-349140.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 99,447,343 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349140.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.